Innovation Pharmaceuticals Inc (IPIX)

[iclight]

How do you presume CTIX decided to move on to a P2 for ovarian patients?

Here's a hint. The secondary outcome of the P1 was for efficacy and the only patients that showed even the smallest hint of efficacy were the ovarian patients.

That PR regarding the disappearing spleen lesion? That was pumping K's efficacy, despite the patient leaving the trial early to most likely seek other treatment.

To say P1 was purely for safety discounts the company PRs to the contrary and highlights the complete misunderstanding of trial endpoints, including the as yet unreported efficacy endpoints in the P1.

It took me all of 10 seconds to google efficacy data on a safety P1 trial treating solid tumors. All companies will report efficacy if it is worth reporting:

http://tetralogicpharma.com/crc/

There was evidence of anti-tumor activity or prolonged disease stabilization in three subjects, one with CRC, one with non-small cell lung cancer, or NSCLC, and one subject with liposarcoma. The liposarcoma subject had disease stabilization for nine months despite progression on three prior therapies.

Fourteen subjects showed anti-tumor activity (as defined by RECIST). One NSCLC subject had a CR (defined as the disappearance of all lesions) and thirteen subjects and PRs (defined as at least a 30% decrease in the sum of all lesions), including responses in anal cancer, CRC, gallbladder cancer, melanoma, NSCLC, ovarian cancer and small cell lung cancer.